Evidence map›Paper›PMID 36161239›Full record

ArticlePhysics and chemistry of the earth (2002)2022

Medicinal plants used for the management of respiratory diseases in Zimbabwe: Review and perspectives potential management of COVID-19.

Elliot Nyagumbo, William Pote, Bridgett Shopo, Trust Nyirenda, Ignatius Chagonda, Ruvimbo J Mapaya, Fabian Maunganidze, William N Mavengere, Cephas Mawere, Ian Mutasa and 4 more

Abstract read
In one paragraph

Article in Physics and chemistry of the earth (2002), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Global burden of reported lower respiratory system fungal infection.Frontiers in cellular and infection microbiology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Foods (Basel, Switzerland) · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Elliot NyagumboDepartment of Biochemistry, Faculty of Medicine and Health Sciences, Midlands State University, Gweru, Zimbabwe.
William PoteEthnobiology-based Drug discovery, Research and Development Trust, Gweru, Zimbabwe.
Bridgett ShopoDepartment of Applied Bioscience and Biotechnology, Faculty of Science and Technology, Midlands State University, Gweru, Zimbabwe.
Trust NyirendaDepartment of Physiology, Faculty of Medicine and Health Sciences, Midlands State University, Gweru, Zimbabwe.
Ignatius ChagondaDepartment of Agriculture Practice, Faculty of Agriculture, Midlands State University, Gweru, Zimbabwe.
Ruvimbo J MapayaDepartment of Applied Bioscience and Biotechnology, Faculty of Science and Technology, Midlands State University, Gweru, Zimbabwe.
Fabian MaunganidzeEthnobiology-based Drug discovery, Research and Development Trust, Gweru, Zimbabwe.
William N MavengereEthnobiology-based Drug discovery, Research and Development Trust, Gweru, Zimbabwe.
Cephas MawereDepartment of Biotechnology, School of Industrial Sciences and Technology, Harare Institute of Technology, Harare, Zimbabwe.
Ian MutasaEthnobiology-based Drug discovery, Research and Development Trust, Gweru, Zimbabwe.
Emmanuel KademetemeDepartment of Physiology, School of Medicine and Health Sciences, Great Zimbabwe University, Masvingo, Zimbabwe.
Alfred MaroyiDepartment of Botany, University of Fort Hare, Alice, South Africa.
Tafadzwa TadereraDepartment of Biomedical Sciences, Physiology Unit, University of Zimbabwe, P.O. Box MP167, Mt Pleasant, Harare, Zimbabwe.
Michael BhebheDepartment of Biochemistry, Faculty of Medicine and Health Sciences, Midlands State University, Gweru, Zimbabwe.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory diseases have in the recent past become a health concern globally. More than 523 million cases of coronavirus disease (COVID19), a recent respiratory diseases have been reported, leaving more than 6 million deaths worldwide since the start of the pandemic. In Zimbabwe, respiratory infections have largely been managed using traditional (herbal) medicines, due to their low cost and ease of accessibility. This review highlights the plants' toxicological and pharmacological evaluation studies explored. It seeks to document plants that have been traditionally used in Zimbabwe to treat respiratory ailments within and beyond the past four decades. Extensive literature review based on published papers and abstracts retrieved from the online bibliographic databases, books, book chapters, scientific reports and theses available at Universities in Zimbabwe, were used in this study. From the study, there were at least 58 plant families comprising 160 medicinal plants widely distributed throughout the country. The Fabaceae family had the highest number of medicinal plant species, with a total of 21 species. A total of 12 respiratory ailments were reportedly treatable using the identified plants. From a total of 160 plants, colds were reportedly treatable with 56, pneumonia 53, coughs 34, chest pain and related conditions 29, asthma 25, tuberculosis and spots in lungs 22, unspecified respiratory conditions 20, influenza 13, bronchial problems 12, dyspnoea 7, sore throat and infections 5 and sinus clearing 1 plant. The study identified potential medicinal plants that can be utilised in future to manage respiratory infections.

Indexed as

Coronavirus disease 2019Medicinal plantsPharmacologyRespiratory disordersToxicologyZimbabwe

Identifiers

PMID36161239
PMCPMC9489988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.